Document is current
Any future updates will be listed below
-
Authors
Bailón, Lucia https://orcid.org/0000-0001-7277-9314
Moltó, José
Curran, Adrian
Cadiñanos, Julen
Carlos Lopez Bernaldo de Quirós, Juan
de Los Santos, Ignacio
Ambrosioni, Juan
Imaz, Arkaitz
Benet, Susana
Suanzes, Paula https://orcid.org/0000-0002-6871-0098
Navarro, Jordi https://orcid.org/0000-0002-7187-0367
González-García, Juan
Busca, Carmen
Pérez-Latorre, Leire
Berenguer, Juan https://orcid.org/0000-0001-8541-8200
García-Fraile, Lucio Jesús
Mejía-Abril, Gina
Miró, Jose M.
Scévola, Sofía
Moreno, Santiago
Domingo, Pere https://orcid.org/0000-0003-1138-5770
Tian, Yuan
Frankot, Michelle
Lim, Daina
Cai, Yanhui
Vendrame, Elena https://orcid.org/0000-0002-5595-1773
Guo, Susan
Wallin, Jeffrey J.
Geleziunas, Romas
SenGupta, Devi
Alarcón-Soto, Yovaninna https://orcid.org/0000-0002-9977-8634
Leal, Isabel
Aranguen, Alvaro
Garcia-Garcia, Margarida
McGowan, Ian https://orcid.org/0000-0002-6470-8476
Brander, Christian https://orcid.org/0000-0002-0548-5778
Arribas, Jose Ramón
Mothe, Beatriz https://orcid.org/0000-0001-9975-407X
,
de Los Santos, Ignacio
Cobarsí, Patricia
Martinez, Cristina
Nieto, Aroa
Perez, Francisco
Puig, Jordi
Cedeño, Samandhy
Clotet, Bonaventura
Grau, Eulalia
Llano, Anuska
Paredes, Roger
Cabero, Jose Luís
Naval, Jordi
Falcó, Vicenç
Planas, Bibiana
Burgos, Joaquin
Buzón, María José
Genescà, Meritxell
Grau, Judith
Borobia, Alberto
Hontañon, Victor
Queiruga, Javier
Mican, Rafael
Seco, Enrique
Diez, Cristina
Gijón, Paloma
Ramirez, Margarita
Martín-Vílchez, Samuel
de Miguel-Cáceres, Alejandro
Serra, José María
De la Torre-Muñoz, Tamara
Ariza, Eva
Ferrer, Anna
Garcia, Benito
Morenilla, Sandra
Niubó, Jordi
Piatti, Camila
Soriano, Irene
Vázquez, Daniel
-
Funding
Funding for this research was provided by:
Gilead Sciences
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 17 February 2025
First Online: 4 March 2025
Competing interests
: C.Brander and B.M. are co-inventors of the HTI immunogen (patent application PCT/EP2013/051596). C.Brander, B.M., and I.M. are co-inventors of US patent Application No. 62/935,519 and US Appl. No. 62/851,546, which have relevance to the vaccine regimen used in this study. B.M. reports consultancy, advisory, and/or speaker fees from AELIX Therapeutics, Gilead Sciences, Janssen, ViiV, and MSD. J.M. reports advisory board and speaker fees and grant support from MSD, AbbVie, Boehringer Ingelheim, Gilead Sciences, ViiV Healthcare, Janssen-Cilag, and Bristol Myers Squibb. A.C. reports advisory and speaker fees and grant support from Gilead Sciences, Janssen, MSD, and ViiV Healthcare. P.S. reports advisory and/or speaker fees and/or support for attending meetings from Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, and ViiV Healthcare, and has received a research grant from ViiV Healthcare, all outside of the submitted work. J.B. reports speaker fees and grant support from Gilead Sciences and MSD. J.C. reports speaker fees and grant support from Gilead Sciences and MSD. J.A. reports advisory board and speaker fees and grant support from Gilead Sciences, Janssen, MSD, ViiV; data and safety monitoring board membership with Grifols and HIPRA; and is an employee of the European AIDS Clinical Society (guidelines coordinator). A.I. reports advisory and speaker fees and grant support from Gilead Sciences, Janssen, MSD, Theratechnologies, and ViiV. S.M. reports speaking fees and research grants from Gilead Sciences, Janssen-Cilag, MSD, and ViiV. P.D. reports lecture and advisory board fees from ViiV Healthcare, MSD, GSK, Roche, Theratechnologies, Janssen & Cilag, and Gilead. Y.C., Y.T., R.G., D.S., D.L. J.J.W., S.G., and E.V. are employees and stockholders of Gilead Sciences, Inc. M.F. is an employee of ClinData Insight Inc, whose services were funded by Gilead Sciences, Inc. I.M. was an employee of AELIX Therapeutics, is currently an employee of Orion Biotechnology and is a consultant for Synklino. M.G.G. was an employee of AELIX Therapeutics at the time the research was conducted. J.M.M. has received consulting honoraria and/or research grants from Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work. J.N. has received honoraria and/or speaking fees and/or financial support for attending conferences from AbbVie, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dome, and ViiV Healthcare outside of the submitted work. C.Brander is the cofounder, shareholder, and CSO of AELIX. J.R.A. reports advisory and speaker fees and grant support from ViiV, Janssen, Gilead Sciences, MSD, and AELIX Therapeutics. The remaining authors declare that the research was conducted in the absence of any conflict of interest.
